Last reviewed · How we verify
COVID-19 treatment — Treatment Landscape & Competitive Intelligence
8 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Combination BNT162b2 and BNT162b2 OMI | combination-bnt162b2-and-bnt162b2-omi | Pfizer | mRNA vaccine | SARS-CoV-2 spike protein | ||
| BNT162b2 | bnt162b2 | Pfizer | vaccine | SARS-CoV-2 virus | ||
| BNT162b5 Bivalent (Original/OMI BA.4/BA.5) | bnt162b5-bivalent-original-omi-ba-4-ba-5 | Pfizer | mRNA vaccine | Spike protein of SARS-CoV-2 | ||
| BNT162b2 (Omi JN.1) | bnt162b2-omi-jn-1 | Pfizer | unknown | unknown | ||
| Famtozinameran 12 Years of age and older | famtozinameran-12-years-of-age-and-older | Pfizer | monoclonal antibody | SARS-CoV-2 virus | ||
| BNT162b2 (2025/2026 formulation) | bnt162b2-2025-2026-formulation | Pfizer | vaccine | SARS-CoV-2 spike protein | ||
| BNT162b2 OMI | bnt162b2-omi | Pfizer | Not specified | Not specified | ||
| qIRV (22/23) | qirv-22-23 | Pfizer | Unknown | Unknown |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 8 drugs in COVID-19 treatment
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in COVID-19 treatment:
- COVID-19 treatment treatment updates — RSS
- COVID-19 treatment treatment updates — Atom
- COVID-19 treatment treatment updates — JSON
Cite this brief
Drug Landscape (2026). COVID-19 treatment — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/covid-19-treatment. Accessed 2026-06-10.
Related
- COVID-19 treatment full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing